MYDA Advisors’s Lipocine LPCN Stock Holding History

MYDA Advisors’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-3,529	Closed	-$92K	–	173
2018 Q1	$92K	Buy	+3,529	New	+$98.2K	0.06%	108

Other funds holding LPCN

JGC

J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

MYDA Advisors's LPCN Position: Q2 2018 in Review

MYDA Advisors sold out of Lipocine (LPCN) in Q2 2018, closing a stake of 3,529 shares — an estimated $92K sold.

MYDA Advisors first reported a position in LPCN in Q1 2018 and held it in 1 quarter. The position peaked at $92K in Q1 2018. 30 funds tracked by Wall St. Rank hold LPCN as of Q2 2018.

MYDA Advisors reported no remaining Lipocine position as of Q2 2018 after selling out during the quarter.
MYDA Advisors sold 3,529 Lipocine shares in Q2 2018, an estimated $92K.
MYDA Advisors first reported a position in Lipocine in Q1 2018 and held it in 1 quarter.
MYDA Advisors's Lipocine position peaked at $92K in Q1 2018.
30 funds tracked by Wall St. Rank held Lipocine as of Q2 2018.

Based on MYDA Advisors's 13F filing for Q2 2018, filed 13 Aug 2018.